Fertram Sigurjonsson observed in 2009 that the skin of the fish and qualities, which are similar to those of
human skin, expedited the latter's regeneration, particularly in the case of acute or
chronic wounds. Based on his discovery, he founded Kereceis in 2013. Kerecis Omega-3 fish skin was cleared for use by the FDA in 2013 for the treatment of chronic and acute wounds. In Europe, Kerecis Omega-3 Wound was first CE marked in 2012. In 2016, Omega3 Wound, a fish
skin treatment developed by Kereceis, was approved by the
US Food and Drug Administration. In 2019, Kerecis acquired Phytoceuticals AG, a Swiss company active in the
life sciences sector, that has since changed its name to Kerecis AG. In 2020, Kerecis received an award given by Vaxtarsprotinn, a joint project of the Confederation of Icelandic Industries, the Confederation of Start-up Companies, Icelandic Research Center, and
Reykjavík University. Kereceis also works on medical research with the
US Armed Forces and provides the grafts to branches of the military. In August 2022, Kerecis raised $100 million in funding from investors, including
Kirkbi, the investment arm of the Christiansen family that founded Lego Group, valuing the company at $620 million. ==References==